Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Published:2018-12 Issue:10 Volume:33 Page:421-426
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Yu Min¹,Zhao Qian¹²,Li Yanying¹,Zhang Shuang³,Xu Yong¹,Gong Youling¹,Zhu Jiang¹,Ding Zhenyu¹,Wang Jin¹,Peng Feng¹,Wang Yongsheng¹,Huang Meijuan¹,Ren Li¹,Lu You¹,Liu Yongmei¹

Affiliation:

1. Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

2. The First People Hospital of Zigong, Chengdu, China.

3. Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2018.2493

Reference27 articles.

1. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

2. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

3. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer

4. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis;BMC Cancer;2023-10-30

2. The effect of refined nursing applied in the nursing room of thoracoscopic lung cancer radical operation in Southwestern China;Food Science and Technology;2021-11-24

3. Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation;International Journal of Cancer;2021-10-26

4. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors;Lung Cancer;2020-12